FDA Approves DEPAKOTE SPRINKLES — AbbVie Inc.

# FDA Approval Alert AbbVie Inc.'s DEPAKOTE SPRINKLES (divalproex sodium) oral formulation received FDA approval on September 12, 1989, establishing the company's foothold in the anticonvulsant market and creating a differentiated sprinkle delivery option that could expand the drug's addressable patient population, particularly among pediatric patients who may benefit from the easier-to-administer formulation.